New therapeutic options for adult chronic immune thrombocytopenic purpura: A brief review

Vox Sanguinis

Volumn 94, Issue 1, 2008, Pages 1-5

  Panzer, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AMG 531; Anti B cell treatment; Chronic autoimmune thrombocytopenia; Eltrombopag; Rituximab; Thrombopoietin mimetics

Indexed keywords

B LYMPHOCYTE ANTIBODY; CYTOKINE RECEPTOR AGONIST; ELTROMBOPAG; IMMUNOGLOBULIN; REMIPLISTIM; RITUXIMAB; STEROID; THROMBOPOIETIN;

ARTHRALGIA; AUTOIMMUNE DISEASE; BLEEDING; BRONCHOSPASM; CARDIOGENIC SHOCK; CELL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; HUMAN; HYPOTENSION; IMMUNOMODULATION; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; PUBLICATION; REVIEW; SERUM SICKNESS; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOCYTOPOIESIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; BENZOIC ACIDS; CARRIER PROTEINS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; SPLENECTOMY;

EID: 37249076495     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2007.00999.x     Document Type: Review

References (32)

1. Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med 2002 346: 995 1008
2. Cooper N, Bussel J: The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006 133: 364 74
3. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H: T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003 9: 1123 24
4. Coopamah MD, Garvey MB, Freedman J, Semple JW: Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev 2003 17: 69 80
5. Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I: The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006 91: 1041 10415
6. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001 97: 2549 54
7. George JN: Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006 4: 1664 72
8. Stasi R, Pagano A, Stipa E, Amadori S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 98: 952 57
9. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S: Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007 2924-2930
10. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG: Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146: 25 33
11. Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR: Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006 85: 400 06
12. Godeau B, Fain O, Porcher R, Lefrere F, Fenaux P, Cheze S, Vekhoff A, Chauveheid M-P, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Miche M, Bierling P: Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase II study. Blood (ASH Annu Meeting Abstracts), 2006 108: 478
13. Ramanarayanan J, Brodzik F, Czuczman MS, Hernandez-Ilizaliturri FJ: Efficacy and safety of rituximab in the treatment of refractory/relapsed idiopathic-thrombocytopenic purpura (ITP): results a meta-analysis of 299 patients. Blood (ASH Annu Meeting Abstracts), 2006 108: 1076
14. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB: Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year. Blood (ASH Annu Meeting Abstracts), 2006 108: 479
15. Stasi R, Stipa E, Forte V, Meo P, Amadori S: Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002 99: 3872 73
16. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ: Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987 80: 33 40
17. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J: Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004 103: 1364 69
18. Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, Louwes H, Vellenga E, de Wolf JT: Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004 103: 500 06
19. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996 87: 4068 71
20. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, Shiraga M, Honda S, Kanakura Y, Matsuzawa Y: Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996 93: 704 06
21. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y: Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002 100: 728 30
22. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98: 3241 48
23. Kuter DJ: New thrombopoietic growth factors. Blood 2007 109: 4607 16
24. Wang B, Nichol JL, Sullivan JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004 76: 628 38
25. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, Christal J, Chen CF, Nichol JL: An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006 135: 547 53
26. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL: AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006 355: 1672 81
27. Bussel JB: Immune thrombocytopenic purpura in Varon D, Michelson A (eds): Platelet Symposium. Israel, Ma'aleh Hachamisha, 2006
28. Kuter D, Bussel J, George J, Aledort L, Lichtin A, Lyons R, Nieva J, Wasser J, Bourgeois E, Kappers-Klunne M, Lefrere F, Schipperus M, Kelly R, Christal J, Guo M, Janet Nichol J. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood (ASH Annu Meeting Abstracts) 2006 108: 476
29. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL: Phase 1 clinical study of Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007 109: 4739 41
30. Bussel J, Provan D, Shamsi T, Cheng G, Kovaleva L, Stone N, Mayer B, Poulin R, Arning M: Eltrombopag raises platelet counts and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura (ITP): a phase III study. Haematologica 2007 92: 143
31. Panzer S, Rieger M, Vormittag R, Eichelberger E, Dunkler D, Pabinger I: Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007 37: 814 819
32. Panzer S, Seel E, Brunner M, Kormoczi GF, Schmid M, Ferenci P, Peck-Radosavljevic M: Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006 77: 513 17